- AdventHealth
As part of Healthcare Innovation’s Advancing Digital Healthcare Delivery, a monthly digital health virtual series with innovators who are transforming healthcare, Rajan Wadhawan, M.D., neonatologist and senior executive officer of AdventHealth for Children and AdventHealth for Women, candidly discussed the clinical challenges of rare diseases and how a new board for the state of Florida is working to improve health outcomes for patients living with these diseases.
“Rare diseases are usually chronic and involve multiple systems, and almost all of these conditions have a genetic cause, which means they are manifesting in infants,” said Wadhawan. Because of these complexities, they are difficult to diagnose and manage, often causing a delay in care.
“Diagnosing a rare disease can take four to five years and oftentimes it includes an earlier misdiagnosis,” he said.
While rare diseases are classified as those that affect less than 200,000 people in the U.S., there are more than 7,000 different types of rare diseases – and each present with their own nuanced conditions and symptoms. All of these combined impacts an immense number of people: nearly 1 in 10 Americans are estimated to be living with rare diseases.
“The knowledge base for every condition is so vast, it is not possible for an average practicing physician to know everything about every rare disease,” Wadhawan said.
During his four-year term on Florida’s newly established Rare Disease Advisory Council (RDAC), Wadhawan will provide his expertise and personal perspective to encourage potential policy changes to make it easier for physicians and patients. This could include developing an online repository of searchable information to improve the diagnosis process and a consortium within the state or region to conduct rare disease research.
“Just like anything in life, there is so much that needs to be done that it can be overwhelming and daunting, but you have to start somewhere,” Wadhawan concludes. “We cannot be frozen by or paralyzed by the enormity of a challenge. If we first examine the areas where we can have the most impact, within the areas where we are experts, we can take it from there.”
As one of 20 representatives on Florida’s RDAC, Wadhawan and his colleagues are working to improve health outcomes for those with a rare disease and making recommendations to state leaders on critical issues, including the need for increased awareness, diagnostic tools and access to affordable treatments and cures.
Recent News
Kidney-tumor patients have an innovative new treatment option, first performed recently by a surgical team at AdventHealth Celebration.
Test Apple Podcast
As the Official Healthcare Provider of the 2024 NASCAR Chicago Street Race, we’re thrilled to support such a memorable experience with this amazing community.
The innovative new treatment targets and destroys tumors using sound beams, noninvasively and without the need for needles and incisions.
A summary of the article goes here. A summary of the article goes here. A summary of the article goes here. A summary of the article goes here.
The innovative new treatment targets and destroys tumors using sound beams, noninvasively and without the need for needles and incisions.
Dr. Corbin on the gut microbiome research study
A genetic test, originally conducted to help better understand her daughter's diagnosis, revealed Samantha Arceneaux carries a genetic variant that virtually guarantees she will develop an aggressive...
Under the leadership of investigator Guru Sonpavde, MD, AdventHealth’s Clinical Research Unit (CRU), a collaborative between the AdventHealth Cancer Institute and AdventHealth Research Institute, is...
The AdventHealth Research Institute recently launched two new clinical studies to better understand and address the needs of healthcare employees who work night shifts.
In January 2024, AdventHealth Celebration neurotologist Michael Seidman, MD, FACS, became the first in Florida and the Southeast to complete a robotics-assisted cochlear implant procedure using the...
The CheckMate 901 Phase III clinical trial results, recently published in the New England Journal of Medicine, found that combining the programmed death 1 (PD1) inhibitor immunotherapy nivolumab with...